Inhibikase Therapeutics (IKT) Total Current Liabilities (2020 - 2025)
Historic Total Current Liabilities for Inhibikase Therapeutics (IKT) over the last 6 years, with Q3 2025 value amounting to $6.7 million.
- Inhibikase Therapeutics' Total Current Liabilities rose 3645.01% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 million, marking a year-over-year increase of 3645.01%. This contributed to the annual value of $3.7 million for FY2024, which is 857.81% up from last year.
- According to the latest figures from Q3 2025, Inhibikase Therapeutics' Total Current Liabilities is $6.7 million, which was up 3645.01% from $8.8 million recorded in Q2 2025.
- In the past 5 years, Inhibikase Therapeutics' Total Current Liabilities ranged from a high of $8.8 million in Q2 2025 and a low of $1.9 million during Q2 2021
- Its 5-year average for Total Current Liabilities is $4.2 million, with a median of $3.7 million in 2022.
- Per our database at Business Quant, Inhibikase Therapeutics' Total Current Liabilities plummeted by 1466.52% in 2023 and then surged by 13753.39% in 2025.
- Over the past 5 years, Inhibikase Therapeutics' Total Current Liabilities (Quarter) stood at $4.1 million in 2021, then fell by 8.85% to $3.7 million in 2022, then fell by 6.95% to $3.4 million in 2023, then grew by 8.58% to $3.7 million in 2024, then skyrocketed by 79.35% to $6.7 million in 2025.
- Its last three reported values are $6.7 million in Q3 2025, $8.8 million for Q2 2025, and $8.6 million during Q1 2025.